Format

Send to

Choose Destination
Transpl Int. 2009 Jul;22(7):681-7. doi: 10.1111/j.1432-2277.2009.00858.x. Epub 2009 Apr 6.

Practical recommendations for the early use of m-TOR inhibitors (sirolimus) in renal transplantation.

Author information

1
Unidad de Transplante Renal, Hospital Clinic i Provincial, Barcelona 08036, Spain. jmcampis@clinic.ub.es

Abstract

m-TOR inhibitors (e.g. sirolimus) are well-tolerated immunosuppressants used in renal transplantation for prophylaxis of organ rejection, and are associated with long-term graft survival. Early use of sirolimus is often advocated by clinicians, but this may be associated with a number of side-effects including impaired wound-healing, lymphoceles and delayed graft function. As transplant clinicians with experience in the use of sirolimus, we believe such side-effects can be limited by tailored clinical management. We present recommendations based on published literature and our clinical experience. Furthermore, guidance is provided on sirolimus use during surgery, both at transplantation and for subsequent operations.

[Indexed for MEDLINE]
Free full text

Supplemental Content

Full text links

Icon for Wiley
Loading ...
Support Center